Fludarabine in Waldenstrom’s macroglobulinemia

References

• Owen RG, Treon SP, Al-Katib A et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin. Oncol. 30(2), 110–115 (2003).
   PubMed Web of Science ®Google Scholar
• Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr. Waldenstrom’s macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer 82(6), 1078–1081 (1998).
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood 112(8), 3052–3056 (2008).
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Landgren O. What causes Waldenstrom’s macroglobulinemia: genetic or immune-related factors, or a combination? Clin. Lymphoma Myeloma Leuk. 11(1), 85–87 (2011).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102(10), 3759–3764 (2003).
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N. Engl. J. Med. 367(9), 826–833 (2012).
   PubMed Web of Science ®Google Scholar
• Gachard N, Parrens M, Soubeyran I et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 27(1), 183–189 (2013).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Treon SP, Alexanian R et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin. Oncol. 30(2), 116–120 (2003).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR, Gertz MA et al. Waldenstrom’s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br. J. Haematol. 108(4), 737–742 (2000).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood 75(10), 1928–1931 (1990).
   PubMed Web of Science ®Google Scholar
• Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res. 46(11), 5953–5958 (1986).
   PubMed Web of Science ®Google Scholar
• Warrell RP Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 4(1), 74–79 (1986).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Kantarjian H, Talpaz M et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74(1), 19–25 (1989).
   PubMed Web of Science ®Google Scholar
• Brockman RW, Cheng YC, Schabel FM Jr, Montgomery JA. Metabolism and chemotherapeutic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res. 40(10), 3610–3615 (1980).
   PubMed Web of Science ®Google Scholar
• Dow LW, Bell DE, Poulakos L, Fridland A. Differences in metabolism and cytotoxicity between 9-β-d arabinofuranosyladenine and 9-β-d-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts. Cancer Res. 40(5), 1405–1410 (1980).
   PubMed Web of Science ®Google Scholar
• Parker WB, Cheng YC. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Mol. Pharmacol. 31(2), 146–151 (1987).
   PubMed Web of Science ®Google Scholar
• White EL, Shaddix SC, Brockman RW, Bennett LL Jr. Comparison of the actions of 9-β-d-arabinofuranosyl-2-fluoroadenine and 9-β-d-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res. 42(6), 2260–2264 (1982).
   PubMed Web of Science ®Google Scholar
• Foran JM, Oscier D, Orchard J et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with ‘low-grade’ non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 17(5), 1574–1579 (1999).
   PubMed Web of Science ®Google Scholar
• Oscier D, Orchard JA, Culligan D et al. The bioavailability of oral fludarabine phosphate is unaffected by food. Hematol. J. 2(5), 316–321 (2001).
   PubMedGoogle Scholar
• Lichtman SM, Etcubanas E, Budman DR et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest. 20(7-8), 904–913 (2002).
   PubMed Web of Science ®Google Scholar
• Leblond V, Lévy V, Maloisel F et al.; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide–doxorubicin–prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98(9), 2640–2644 (2001).
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZ, Coiffier B et al. Multicenter Phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma. J. Clin. Oncol. 17(2), 546–553 (1999).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98(1), 41–48 (2001).
   PubMed Web of Science ®Google Scholar
• Leblond V, Johnson S, Chevret S et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J. Clin. Oncol. 31(3), 301–307 (2013).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, O’Brien S, Kantarjian H et al. Fludarabine therapy in Waldenstrom’s macroglobulinemia. Am. J. Med. 95(1), 49–52 (1993).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Gherlinzoni F, Bendandi M et al. Fludarabine treatment in resistant Waldenstrom’s macroglobulinemia. Eur. J. Haematol. 54(2), 120–123 (1995).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Hoering A, Gertz MA et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 113(4), 793–796 (2009).
   PubMed Web of Science ®Google Scholar
• Thalhammer-Scherrer R, Geissler K, Schwarzinger I et al. Fludarabine therapy in Waldenstrom’s macroglobulinemia. Ann. Hematol. 79(10), 556–559 (2000).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kantarjian H, Weber D et al. Primary therapy of Waldenstrom’s macroglobulinemia with 2-chlorodeoxyadenosine. J. Clin. Oncol. 12(12), 2694–2698 (1994).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A et al. Treatment of Waldenstrom’s macroglobulinemia with rituximab. J. Clin. Oncol. 20(9), 2327–2333 (2002).
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 113(16), 3673–3678 (2009).
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res. 7(11), 3580–3589 (2001).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hamilos G, Efstathiou E et al. Treatment of Waldenstrom’s macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk. Lymphoma 44(6), 993–996 (2003).
   PubMed Web of Science ®Google Scholar
• Tamburini J, Lévy V, Chaleteix C et al. Fludarabine plus cyclophosphamide in Waldenstrom’s macroglobulinemia: results in 49 patients. Leukemia 19(10), 1831–1834 (2005).
   PubMed Web of Science ®Google Scholar
• Furlan A, Villanova F, Pietrogrande F, Celadin M, Sanzari M, Vianello F. Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro. Leuk. Lymphoma 51(1), 107–113 (2010).
   PubMed Web of Science ®Google Scholar
• Tam CS, Wolf M, Prince HM et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 106(11), 2412–2420 (2006).
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Benevolo G, Varettoni M et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 118(2), 434–443 (2012).
   PubMed Web of Science ®Google Scholar
• Compain L, Levy V, Tamburini J et al. Fludarabine plus cyclophosphamide and rituximab (FCR) in Waldenstrom’s macroglobulinemia: results in 62 patients. Hématologie 17(Suppl. 1), Abstract 05-39 (2011).
   Google Scholar
• Gill S, Carney D, Ritchie D et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann. Oncol. 21(2), 331–334 (2010).
   PubMed Web of Science ®Google Scholar
• Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 89(5), 308–318 (2010).
   PubMed Web of Science ®Google Scholar
• Leleu X, Soumerai J, Roccaro A et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J. Clin. Oncol. 27(2), 250–255 (2009).
   PubMed Web of Science ®Google Scholar
• Morrison VA, Rai KR, Peterson BL et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J. Clin. Oncol. 20(18), 3878–3884 (2002).
   PubMed Web of Science ®Google Scholar
• Bowcock SJ, Rassam SM, Lim Z, Ward SM, Ryali MM, Mufti GJ. High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders. Br. J. Haematol. 134(2), 242–243 (2006).
   PubMed Web of Science ®Google Scholar
• Desikan R, Dhodapkar M, Siegel D et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom’s macroglobulinaemia. Br. J. Haematol. 105(4), 993–996 (1999).
   PubMed Web of Science ®Google Scholar
• Tournilhac O, Cazin B, Leprètre S et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 103(1), 363–365 (2004).
   PubMed Web of Science ®Google Scholar
• Michallet M, Thiébaut A, Dreger P et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br. J. Haematol. 108(3), 595–601 (2000).
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Rossi V et al. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia 18(1), 57–62 (2004).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Moreau P, Harris B et al. A multicenter Phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin. Cancer Res. 18(18), 5043–5050 (2012).
   PubMed Web of Science ®Google Scholar
• Leblond V, Ben-Othman T, Deconinck E et al.; Groupe Coopératif Macroglobulinémie. Activity of fludarabine in previously treated Waldenstrom’s macroglobulinemia: a report of 71 cases. J. Clin. Oncol. 16(6), 2060–2064 (1998).
   PubMed Web of Science ®Google Scholar